The FDA approved Idacio as a biosimilar to Humira, a TNF inhibitor with indications for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn ...

The technologies have different mechanisms of action. Adalimumab, etanercept, infliximab, certolizumab pegol and golimumab all inhibit the activity of tumour necrosis factor (TNF)‑alpha, a ...

A rare case of adalimumab-induced pustular psoriasis in a hidradenitis suppurativa patient was successfully treated with ...

Key Takeaways. Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015 ...

The researchers’ simulation found that repeated courses of intranodular injections of adalimumab are likely to be cost-effective for treating progressive early-stage Dupuytren’s disease.

Pariser DM, Lebwohl MG, Jaworski J, et al. CT-P17 adalimumab biosimilar in patients with moderate-to-severe chronic plaque psoriasis: An open-label extension of a phase 3 interchangeability study.

Safety. Adverse events were seen in 70.0%-70.9% of the olokizumab groups, 65.4% of those receiving adalimumab, and 63.4% of the placebo group. Serious adverse events overall weren't notably more ...

Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol . 2023;89(4):677 ...